Featured Archives - Page 3 of 14 - Halberd Corporation

Dec 5 2022

“The Street Podcast” Features Halberd’s “Groundbreaking” Cancer Treatment Approach. Listen Now!

By Admin|2022-12-04T16:15:09-05:00December 5th, 2022|Featured, Investor News, Medical, News|0 Comments

CEO William Hartman and CTO Mitchell Felder report successful application of Halberd’s patented methodology for Cancer Antigen Eradication Treatment. Jackson Center, PA December 5, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments, successfully ...

Nov 30 2022

Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant

By Admin|2022-11-30T19:22:58-05:00November 30th, 2022|Featured, Investor News, Medical, News|0 Comments

UPDATED. Boosts effectiveness by 44.4%% of commercially available Covid antibody in cocktail Jackson Center, PA November 30, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Covid research has led to a scientific article titled, “A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant.” The article has been peer ...

Nov 17 2022

Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint By Eradicating Cancer Disease Antigen Linked to Breast Cancer

By Admin|2022-11-17T05:15:05-05:00November 17th, 2022|Featured, Investor News, Medical, News|0 Comments

Halberd Successful In Laboratory Tests In Eradicating All Five of The Top Cancer Disease Antigens Attempted To Date Jackson Center, PA, November 17, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in ...

Nov 14 2022

Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals

By Admin|2022-11-14T10:09:21-05:00November 14th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Accelerated Sales of HALB's Patented Products through newly formed “The Hamden Group” Jackson Center, PA, November 14, 2022 – Halberd Corporation (OTC-PINK: HALB) has signed a contract with the Hamden Group. The Hamden Group is a newly formed corporation which consists of members of the Croden family and Darren Hamans, who have extensive experience in the ...

Sep 27 2022

Halberd Enters Strategic Alliance for Longevity, Alzheimer’s Disease, and Cancer Early Detection, Prevention and Treatment

By Admin|2022-09-26T21:24:04-04:00September 27th, 2022|Featured, Investor News, News, Press Releases|1 Comment

Jackson Center, PA, September 27, 2022 – Halberd Corporation (OTC-PINK: "HALB”) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”. The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease ...

Aug 4 2022

NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology

By Admin|2022-08-03T21:28:03-04:00August 4th, 2022|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 04, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd’s research work in the development of treatments for Traumatic Brain Injury (TBI)/chronic traumatic encephalopathy (CTE) sustained by current and retired players. Traumatic brain injuries ...

Jul 20 2022

Halberd Corp. Launches “Halberd Cancer Therapeutics, LTD” Wholly Owned Subsidiary

By Admin|2022-07-19T20:21:05-04:00July 20th, 2022|Featured, Investor News, News|0 Comments

Jackson Center, PA, July 20, 2022 – Halberd Corporation (OTC-PINK: "HALB”) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd’s patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses. For now, the new entity will be staffed by Halberd personnel ...

Jul 12 2022

Halberd Corporation Update, CEO Letter and 2022 Expectations

By Admin|2022-07-11T19:19:34-04:00July 12th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Q2 Accomplishments and a Look to the Future Jackson Center, PA, July 12, 2022. Halberd Corporation (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. The accomplishments for the Second Quarter ending June 30, 2022, are as follows: 2Q ACHIEVEMENTS Added an animal testing expert (DVM/PhD) ...

Jun 21 2022

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

By Admin|2022-06-21T05:23:46-04:00June 21st, 2022|Featured, Investor News, News|0 Comments

Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment. Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided ...

Jun 8 2022

Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification

By Admin|2022-06-07T21:21:57-04:00June 8th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, June 8, 2022 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd’s patented extracorporeal disease eradication processes. Consistent with its press release of May 18, 2022, Halberd commenced its pursuits with mdi ...

Previous 234 Next